Clinical Trial Update: Observational Post-Authorisation Safety Study of Asenapine (Sycrest)

View source ↗

Summary

The document reports the completion of an observational post-authorization safety study evaluating the safety of asenapine (Sycrest) in manic disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Manic Episode

Drugs mentioned

• Sycrest (asenapine maleate)

Snippet

Sponsor: Professor Saad Shakir | Conditions: Manic Disorder | Status: COMPLETED